Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 30; p. v494
Main Authors Conter, H.J., MacDonald, L.D., Fiset, S., Bramhecha, Y.M., Chaney, M., Rosu, G.N.
Format Journal Article
LanguageEnglish
Published 01.10.2019
Online AccessGet full text

Cover

Author Fiset, S.
Rosu, G.N.
Conter, H.J.
Bramhecha, Y.M.
MacDonald, L.D.
Chaney, M.
Author_xml – sequence: 1
  givenname: H.J.
  surname: Conter
  fullname: Conter, H.J.
– sequence: 2
  givenname: L.D.
  surname: MacDonald
  fullname: MacDonald, L.D.
– sequence: 3
  givenname: S.
  surname: Fiset
  fullname: Fiset, S.
– sequence: 4
  givenname: Y.M.
  surname: Bramhecha
  fullname: Bramhecha, Y.M.
– sequence: 5
  givenname: M.
  surname: Chaney
  fullname: Chaney, M.
– sequence: 6
  givenname: G.N.
  surname: Rosu
  fullname: Rosu, G.N.
BookMark eNpFUUtr3DAQdiGFJml_QHuaU0lgnchP2b0F97GBbbuwOfRmZGmEFSTLSPKGza-vdrfQ08A3w_eY7yq5mOyESfIxI3cZaYt7NkWA3xvxmlfFHSnKi-SStHmR0qoo3yVX3j8TQuo2by_ffNoxieEAbBKAUirO-AEc-kUHD1ZCGBG4NYOaWFB2OkJft3_S3eL2as_4CmY0g7NavS6GDScaNQV0RoWAUwBtX0BYH0kOXNt5tH4emVEC4abbPtzGY_DL8Iw8yr2oMAITezZxFCcqg4H5EJU5-KghICzGLs5_ga1DrUx05f7blc6ak-ERZxYsR60XzRxw5riarGFws-662xX82nWbbgWDZkLgcR8F3Qo-w8_dY7qOeUfrgn-fvJVMe_zwb14nT9-_PXXrdPP7x2P3sEl5U5UpyxuZ0aagZc7ztuHxnQ0RA6WUcZqjoI3AmiBmhSiFbGtB6yqXWU5bSaq6bIvrJDvTcme9dyj72SkTc_UZ6Y999uc--3Offeyz-Avtv5-b
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.1093/annonc/mdz253.034
DatabaseName CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 10_1093_annonc_mdz253_034
GroupedDBID ---
-E4
.2P
.86
.I3
.XZ
.ZR
08P
0R~
0U7
1TH
23M
2WC
4.4
482
53G
5GY
5VS
5WA
6J9
70D
AAEDW
AAGQS
AAJKP
AAJQQ
AAKAS
AAKUH
AALRI
AAMVS
AAOGV
AAPNW
AAUQX
AAXUO
AAYWO
AAYXX
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNGD
ABNKS
ABOCM
ABQLI
ABSMQ
ABZBJ
ACGFO
ACGFS
ACPQN
ACPRK
ACUKT
ACUTO
ACVFH
ADBBV
ADCNI
ADEYI
ADHKW
ADHZD
ADOCK
ADRTK
ADVLN
ADYVW
ADZCM
ADZXQ
AEGPL
AEGXH
AEHUL
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AEUPX
AEWNT
AFETI
AFIYH
AFJKZ
AFOFC
AFPUW
AFSHK
AGCQF
AGINJ
AGKEF
AGKRT
AGQPQ
AGSYK
AHMBA
AHXPO
AIAGR
AIGII
AIJHB
AITUG
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AMRAJ
APIBT
APWMN
APXCP
AQKUS
ASPBG
ATTQO
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BGNMA
BHONS
BTRTY
BVRKM
BZKNY
C1A
CAG
CDBKE
CITATION
CKLRP
COF
CS3
CZ4
DAKXR
DIK
DILTD
DL5
D~K
E3Z
EBS
EE~
EJD
EX3
FDB
FEDTE
GJXCC
GX1
H13
H5~
HVGLF
HW0
HZ~
I09
IH2
IHE
J21
KAQDR
KDC
KOM
LAK
M-Z
M41
M4Y
MBLQV
MHKGH
N9A
NGC
NOYVH
NTWIH
NU0
NVLIB
O9-
OAWHX
ODMLO
OJQWA
OK1
OVD
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RNI
ROL
RPX
RW1
RZC
RZE
RZF
RZO
SDH
TCURE
TEORI
TR2
U2A
W8F
WOQ
WOW
X7H
YAYTL
YFH
YKOAZ
ZKX
ZXP
~91
ID FETCH-LOGICAL-c854-a28f1783742c298cafe80db777ac72ed78de60ee13d4df96d7652f1279f056493
ISSN 0923-7534
IngestDate Tue Jul 01 02:09:41 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c854-a28f1783742c298cafe80db777ac72ed78de60ee13d4df96d7652f1279f056493
OpenAccessLink https://doi.org/10.1093/annonc/mdz253.034
ParticipantIDs crossref_primary_10_1093_annonc_mdz253_034
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-10-00
PublicationDateYYYYMMDD 2019-10-01
PublicationDate_xml – month: 10
  year: 2019
  text: 2019-10-00
PublicationDecade 2010
PublicationTitle Annals of oncology
PublicationYear 2019
SSID ssj0006929
Score 2.298775
SourceID crossref
SourceType Index Database
StartPage v494
Title Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3db9MwEMDNNiTEC-JTY3zoHhDaSJM1X03C28iYurGiSi3SeKocx1GLmqRqkyH613O2kzTdQGK8RJYbnZ3cr_HZPt8R8s73Izfq-lznsQyq7bp65JmJ7jHqBq6bmNQRB4UHX3v9b87FlXu1s6u1vJbKIjLY-o_nSv5Hq1iHehWnZO-g2UYoVmAZ9YtX1DBe_0nHI5oIj0ux9s1FKAiRuh2nz-VcOWgImxKbxblvYxeeDq_0UYmfh2sqU5sveBqJvD3rMqVRFYlJ-scUhXASmOc_tVh6tP9i83wxzVeLKU1nsTRMw-GJWFOYZdqqjH5IrxB1Uq52KxDiUl5QcWhpxjR8F7NYK8oUH0064g2XfC6Tii033W6Ou0xxnCxysa8gHWWZyHmU5SkVLffDEFuWII_Cy1AUorn4hIr7sGlJoWB6MDrX-5pIArxUEauMW3Gj84xt7SzIcF1SQN-4MFoL9ptV9EvjtPnhbLZS2zmjpurTkqZTztRO2ndjYLRXVsyg8dFrlkgtW8fpnNMeLapdJPW5v3ZUhuZb45CK0UWzDB8CC2m8tlzb6FaitqJ-3xiNGx9J5R1gT5SQiRIxQRG75L6FcyK5fnD-pTE7eoGlAktWna638AP7WIk43vSiZYS1rKnxY_KomgbBiWL6Cdnh2VPyYFA5ejy7d6DQBkQIarShYgTyBJAQaKEtqtpod2ALbCmmDTYg2CDAhptgwyFifYQ3Qw01CKihhlqK2kANEmqooP4ILaSb7gqkZYe3kYYGaThEoI86IGHuQIUyKJQ78B4kxlBh_JyMzz6Pw75epTHRme86OrX8xPR823MsZgU-w9fnd-PI8zzKPIvHnh_zXpdz046dOAl6sddzrcS0vCDByYkT2C_IHqqP7xMIaIyGDU1QhOlYHqdoqTDTcWg3CahpJy_Jh1qtk4UKVjP5K0YHd7n5FXm4-Ye8JnvFsuRv0BovoreSwt9FIOpk
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+efficacy+results+of+the+combination+of+DPX-Survivac%2C+pembrolizumab+and+intermittent+low+dose+cyclophosphamide+%28CPA%29+in+subjects+with+advanced+and+metastatic+solid+tumours%3A+Preliminary+results+from+the+hepatocellular+carcinoma+%28HCC%29%2C+NSCLC%2C+bladder+cancer%2C+%26+MSI-H+cohorts&rft.jtitle=Annals+of+oncology&rft.au=Conter%2C+H.J.&rft.au=MacDonald%2C+L.D.&rft.au=Fiset%2C+S.&rft.au=Bramhecha%2C+Y.M.&rft.date=2019-10-01&rft.issn=0923-7534&rft.volume=30&rft.spage=v494&rft_id=info:doi/10.1093%2Fannonc%2Fmdz253.034&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_annonc_mdz253_034
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon